-

SpineGuard Obtains European Patent on Automatic Bone Breach Detection by DSG, Applicable to Orthopedic Power Drills and Robots

PARIS & BOULDER, Colo.--(BUSINESS WIRE)--Regulatory News:

SpineGuard (FR0011464452 - ALSGD) (Paris:ALSGD), an innovative company that deploys its DSG® (Dynamic Surgical Guidance) local conductivity sensing technology to secure and streamline the placement of bone implants, today announced that its patent application directed to protect algorithms for automatic detection of breaches during bone drilling, enhance safety of bone drilling power tools thanks to a DSG-enabled active safety stop, has received an intention to grant from European Patent Office.

Stéphane Bette, Deputy CEO and cofounder of SpineGuard, stated: “On the heels of our US allowed patent last July, this European validation for a technically complementary patent is timely to support ongoing strategic discussions with the industry, in particular regarding applications to power drilling tools and robots.”

Since its inception, SpineGuard has developed and maintained a significant IP portfolio currently including 11 patent families totaling 72 patents and applications as well as 3 trademarks, in the major geographies such as Europe, USA, China and Japan. The new patent object of this communication and about to be granted, is the first obtained by SpineGuard in Europe belonging to the category of DSG technology exploitation in smart surgical tools. Codesigned and validated with the ISIR (Institute for Intelligent Systems and Robotics) of Sorbonne University, CNRS and INSERM, this patent describes algorithms analyzing the DSG measurements to determine objectively and in real-time a pending breach during a bone drilling. SpineGuard had previously communicated in March 2023 on the experimental results obtained from utilization of such algorithms, where 100% of the blindly executed drillings could be stopped within a corridor considered as clinically safe, i.e.: 2 millimeters on each side of the interface between bone and the spinal canal with a mean distance of 0.7 millimeters.

About SpineGuard®

Founded in 2009 in France and the USA by Pierre Jérôme and Stéphane Bette, SpineGuard is an innovative company deploying its proprietary radiation-free real time sensing technology DSG® (Dynamic Surgical Guidance) to secure and streamline the placement of implants in the skeleton. SpineGuard designs, develops and markets medical devices embedding its technology. Over 100,000 surgical procedures have been secured worldwide thanks to DSG® and 39 studies published in peer-reviewed scientific journals have demonstrated the multiple benefits DSG® offers to patients, surgeons, surgical staff and hospitals. Building on these strong fundamentals and several strategic partnerships, SpineGuard is expanding the scope of its DSG® technology to the treatment of scoliosis via anterior approach, sacroiliac joint fusion, dental implantology and innovations such as the « smart » pedicle screw and power drill or surgical robotics. DSG® was co-invented by Maurice Bourlion, Ph.D., Ciaran Bolger, M.D., Ph.D., and Alain Vanquaethem, Biomedical Engineer. SpineGuard has engaged in multiple ESG initiatives. For further information, visit www.spineguard.com

Disclaimer

The SpineGuard securities may not be offered or sold in the United States as they have not been and will not be registered under the Securities Act or any United States state securities laws, and SpineGuard does not intend to make a public offer of its securities in the United States. This is an announcement and not a prospectus, and the information contained herein does and shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in the United States in which such offer, solicitation or sale would be unlawful prior to registration or exemption from registration.

Contacts

SpineGuard
Pierre Jérôme
CEO & Chairman
Tel: +33 1 45 18 45 19
p.jerome@spineguard.com

SpineGuard
Anne-Charlotte Millard
CFO
Tél. : 01 45 18 45 19
ac.millard@spineguard.com

NewCap
Investor Relations & Financial Communication
Mathilde Bohin / Aurélie Manavarere
Tel: +33 1 44 71 94 94
spineguard@newcap.eu

SpineGuard

BOURSE:ALSGD

Release Versions

Contacts

SpineGuard
Pierre Jérôme
CEO & Chairman
Tel: +33 1 45 18 45 19
p.jerome@spineguard.com

SpineGuard
Anne-Charlotte Millard
CFO
Tél. : 01 45 18 45 19
ac.millard@spineguard.com

NewCap
Investor Relations & Financial Communication
Mathilde Bohin / Aurélie Manavarere
Tel: +33 1 44 71 94 94
spineguard@newcap.eu

More News From SpineGuard

SpineGuard: Official Launch of Three New PediGuard® Models During the Annual Scoliosis Meeting in China

PARIS & BOULDER, Colo.--(BUSINESS WIRE)--Regulatory News: SpineGuard (FR0011464452 - ALSGD), an innovative company that deploys its DSG® (Dynamic Surgical Guidance) local conductivity sensing technology to secure and streamline the placement of bone implants, today announced the official launch of the newly cleared Curved and XS PediGuard models, in Nanjing (China), during the 2026 Chinese Scoliosis Annual Meeting in conjunction with French Spine Society. PediGuard has been highlighted by Profe...

SpineGuard and Omnia Medical Complete US Asset Transfer and Enter Exclusive Distribution Agreement for PediGuard®

MORGANTOWN, W. Va. & BOULDER, Colo. & PARIS--(BUSINESS WIRE)--Regulatory News: SpineGuard (FR0011464452 – ALSGD), an innovative company specializing in Dynamic Surgical Guidance (DSG®) technology to enhance the safety and efficiency of bone implant placement, and Omnia Medical, an orthopedic implant company focused on innovative spine and sacroiliac solutions, today announced the completion of the transfer of SpineGuard Inc assets and the execution of an exclusive distribution U.S. distribution...

SpineGuard Announces Full-Year 2025 Financial Results, First Quarter 2026 Sales, and the Set-Up of a Bond Financing

PARIS & BOULDER, Colo.--(BUSINESS WIRE)--Regulatory News: SpineGuard (FR0011464452 - ALSGD), an innovative company that deploys its DSG® (Dynamic Surgical Guidance) sensing technology to secure and streamline the placement of bone implants, today announces its full-year 2025 financial results for the year ended December 31, 2025, as approved by the Board of Directors on April 07, 2026, its first quarter 2026 sales, as well as the completion of a bond financing of up to €1 million. 2025 Financia...
Back to Newsroom